Cash Flow Theravance Biopharma, Inc. Cash flow Statement
Figures in Million
Consolidated Cash Flow Results
Dec'24
Dec'23
Dec'22
Dec'21
Dec'20
Dec'19
No of Months
12
12
12
12
12
12
Profit Before Tax
-44.00
-49.00
-92.00
-265.00
-286.00
-241.00
Adjustment
0.00
0.00
0.00
0.00
0.00
0.00
Changes In working Capital
20.00
-8.00
42.00
-39.00
-39.00
-45.00
Cash Flow after changes in Working Capital
0.00
0.00
0.00
0.00
0.00
0.00
Cash Flow from Operating Activities
-11.00
-26.00
-186.00
-207.00
-250.00
-238.00
Cash Flow from Investing Activities
12.00
-32.00
1,154.00
124.00
10.00
-83.00
Cash Flow from Financing Activities
-2.00
-198.00
-758.00
91.00
263.00
1.00
Net Cash Inflow / Outflow
-1.00
-258.00
208.00
8.00
23.00
-319.00
Opening Cash & Cash Equivalents
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
0.00
0.00
0.00
0.00
0.00
0.00
Closing Cash & Cash Equivalent
0.00
0.00
0.00
0.00
0.00
0.00
Figures in USD Million
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of Theravance Biopharma, Inc.
Figures in Million
consolidated Cash Flow Results
Change(USD)
Change(%)
Profit Before Tax
-44.614
-132.065
88.00
66.22%
Adjustment
0
0
0.00
0.00%
Changes In working Capital
20.355
10.922
10.00
86.37%
Cash Flow after changes in Working Capital
0
0
0.00
0.00%
Cash Flow from Operating Activities
-11.535
-20.075
9.00
42.54%
Cash Flow from Investing Activities
12.284
-69.769
81.00
117.61%
Cash Flow from Financing Activities
-2.497
74.536
-76.00
-103.35%
Net Cash Inflow / Outflow
-1.748
-15.308
14.00
88.58%
Opening Cash & Cash Equivalents
0
0
0.00
0.00%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
0
0
0.00
0.00%
Closing Cash & Cash Equivalent
0
0
0.00
0.00%
Cash Flow - Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is 57.27% vs 85.56% in Dec 2023
Dec'24
Dec'23
Change(%)
Cash Flow from Operating Activities
-11.54
-27.00
57.27%
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
